• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社论:非酒精性脂肪性肝病患者的年龄与纤维化无创标志物:是时候调整时钟了?

Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?

作者信息

Stine Jonathan G, Rinella Mary E

机构信息

Division of Gastroenterology & Hepatology, University of Virginia, Charlottesville, Virginia, USA.

Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

出版信息

Am J Gastroenterol. 2017 May;112(5):752-754. doi: 10.1038/ajg.2017.60.

DOI:10.1038/ajg.2017.60
PMID:28469217
Abstract

Despite the widespread prevalence of nonalcoholic fatty liver disease, diagnostic uncertainty of noninvasive tests to detect those with more advanced disease remains an important unmet need. Numerous predictive models have been developed, many of which incorporate age as a covariate. Index derivation studies typically have not included young adults or the elderly and the predictive utility of these models may not be equivalent across the age spectrum. New cutoffs for advanced fibrosis in those >65 have been proposed and validated in a recent study but will require external validation.

摘要

尽管非酒精性脂肪性肝病普遍流行,但检测病情更严重患者的非侵入性检查在诊断上仍存在不确定性,这仍是一个重要的未满足需求。已经开发了许多预测模型,其中许多将年龄作为协变量纳入。指数推导研究通常未纳入年轻人或老年人,这些模型在整个年龄范围内的预测效用可能并不相同。最近的一项研究提出并验证了65岁以上人群晚期纤维化的新临界值,但仍需要外部验证。

相似文献

1
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?社论:非酒精性脂肪性肝病患者的年龄与纤维化无创标志物:是时候调整时钟了?
Am J Gastroenterol. 2017 May;112(5):752-754. doi: 10.1038/ajg.2017.60.
2
Liver fibrosis markers of nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的肝纤维化标志物
World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427.
3
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
4
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的诊断和评估,包括无创生物标志物和瞬时弹性成像。
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
5
The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.无创评分在评估 1 型糖尿病患者非酒精性脂肪性肝病和肝纤维化程度中的应用。
Hepatol Int. 2018 Jan;12(1):37-43. doi: 10.1007/s12072-017-9840-z. Epub 2018 Jan 9.
6
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患儿肝纤维化评分的评估
Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25.
7
Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.血清标志物模型的开发以提高非酒精性脂肪性肝病中晚期纤维化的诊断准确性:新型LINKI算法与现有算法的比较
PLoS One. 2016 Dec 9;11(12):e0167776. doi: 10.1371/journal.pone.0167776. eCollection 2016.
8
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.非酒精性脂肪性肝病中的肝纤维化——具有预后意义的诊断挑战
World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077.
9
Current status of fibrosis markers.纤维化标志物的现状。
Curr Opin Gastroenterol. 2014 May;30(3):253-9. doi: 10.1097/MOG.0000000000000059.
10
A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease.小儿非酒精性脂肪性肝病无创肝纤维化检测的综合综述
Curr Gastroenterol Rep. 2015 Jun;17(6):23. doi: 10.1007/s11894-015-0447-z.

引用本文的文献

1
Liver, ageing and disease.肝脏、衰老与疾病。
Nat Rev Gastroenterol Hepatol. 2025 Jul 28. doi: 10.1038/s41575-025-01099-z.
2
Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring.纤维化 4 指数和非酒精性脂肪性肝病纤维化评分作为一种非侵入性肝纤维化评分工具的诊断作用。
Medicine (Baltimore). 2024 Oct 25;103(43):e40214. doi: 10.1097/MD.0000000000040214.
3
AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise training.
AMPED 研究:不同剂量有氧运动训练的随机对照试验方案。
Hepatol Commun. 2024 Jun 19;8(7). doi: 10.1097/HC9.0000000000000464. eCollection 2024 Jul 1.
4
Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine.体力活动与非酒精性脂肪性肝病:美国运动医学学会圆桌会议声明。
Med Sci Sports Exerc. 2023 Sep 1;55(9):1717-1726. doi: 10.1249/MSS.0000000000003199.
5
Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis.纤溶酶原激活物抑制剂在伴有失代偿性 NASH 肝硬化的肝移植受者中显著升高。
BMJ Open Gastroenterol. 2021 Jul;8(1). doi: 10.1136/bmjgast-2021-000683.
6
Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease.打破非酒精性脂肪性肝病患者身体活动障碍。
Dig Dis Sci. 2021 Oct;66(10):3604-3611. doi: 10.1007/s10620-020-06673-w. Epub 2020 Oct 23.
7
Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH.非酒精性脂肪性肝炎血栓形成的健身干预(NASHFit):一项关于监督有氧运动计划以降低非酒精性脂肪性肝炎患者凝血风险升高的随机对照试验的研究方案。
Contemp Clin Trials Commun. 2020 Apr 4;18:100560. doi: 10.1016/j.conctc.2020.100560. eCollection 2020 Jun.
8
Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease.运动可减轻脂肪性肝病中核糖体蛋白 S6 磷酸化。
Dig Dis Sci. 2020 Nov;65(11):3238-3243. doi: 10.1007/s10620-020-06226-1. Epub 2020 Apr 1.
9
Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.实施“先FIB-4”策略对基层医疗转诊的非酒精性脂肪性肝病患者诊疗路径的影响
Hepatol Commun. 2019 Jul 29;3(10):1322-1333. doi: 10.1002/hep4.1411. eCollection 2019 Oct.